Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

L-BC virus persists in the budding yeast Saccharomyces cerevisiae, whereas other viruses from the family Totiviridae infect a diverse group of organisms including protists, fungi, arthropods, and vertebrates. The presence of totiviruses alters the fitness of the host organisms, for example, by maintaining the killer system in yeast or increasing the virulence of Leishmania guyanensis. Despite the importance of totiviruses for their host survival, there is limited information about Totivirus structure and assembly. Here we used cryo-electron microscopy to determine the structure of L-BC virus to a resolution of 2.9 Å. The L-BC capsid is organized with icosahedral symmetry, with each asymmetric unit composed of two copies of the capsid protein. Decamers of capsid proteins are stabilized by domain swapping of the C-termini of subunits located around icosahedral fivefold axes. We show that capsids of 9% of particles in a purified L-BC sample were open and lacked one decamer of capsid proteins. The existence of the open particles together with domain swapping within a decamer provides evidence that Totiviridae capsids assemble from the decamers of capsid proteins. Furthermore, the open particles may be assembly intermediates that are prepared for the incorporation of the virus (+) strand RNA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391438PMC
http://dx.doi.org/10.1038/s42003-022-03793-zDOI Listing

Publication Analysis

Top Keywords

l-bc virus
12
capsid proteins
12
decamers capsid
8
domain swapping
8
open particles
8
capsid
6
structures l-bc
4
virus
4
open
4
virus open
4

Similar Publications

Highly stable L-BC capsids with versatile packing potential.

Front Bioeng Biotechnol

September 2024

Laboratory of Nucleic Acid Biochemistry, Department of Biochemistry and Molecular Biology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

Article Synopsis
  • Virus-like particles (VLPs) serve as promising tools for vaccines and nanodelivery systems due to their efficient production and versatile functionalization options.
  • L-BC VLPs synthesized from bacteria and yeast show good size stability across various buffers, ionic strengths, and temperatures, with yeast-derived VLPs performing better under high temperatures.
  • Both VLP types effectively encapsulated molecules like the red fluorescent protein mCherry and the antimicrobial peptide nisin, highlighting their potential for versatile applications in nanobiotechnology.
View Article and Find Full Text PDF

Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related.

View Article and Find Full Text PDF

We characterized previously identified RNA viruses (L-A, L-BC, 20S, and 23S), L-A-dependent M satellites (M1, M2, M28, and Mlus), and M satellite-dependent killer phenotypes in the Saccharomyces cerevisiae 100-genomes genetic resource population. L-BC was present in all strains, albeit in 2 distinct levels, L-BChi and L-BClo; the L-BC level is associated with the L-BC genotype. L-BChi, L-A, 20S, 23S, M1, M2, and Mlus (M28 was absent) were in fewer strains than the similarly inherited 2µ plasmid.

View Article and Find Full Text PDF

Patients with solid tumors have been a risk group since the beginning of the SARS-CoV-2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influence the development of post-vaccination antibodies. This study prospectively analyzed 89 patients under chemotherapy and/or immunotherapy, who received two doses of the mRNA-1237 vaccine, and were compared with a group of 26 non-cancer individuals.

View Article and Find Full Text PDF
Article Synopsis
  • Mass vaccination campaigns have effectively lowered COVID-19 cases and severity, and this study examined the immune responses of patients with primary antibody deficiencies (PAD) after receiving three doses of the mRNA-1273 vaccine.
  • Patients were categorized into groups based on their specific immunodeficiencies, and while unclassified PAD (unPAD) patients and healthy controls showed similar antibody responses after two doses, those with common variable immunodeficiency (CVID) exhibited weaker responses.
  • The third vaccine dose improved antibody levels in most PAD patients but had little effect on enhancing cellular immunity, highlighting the need for individualized monitoring and treatment strategies for PAD individuals.
View Article and Find Full Text PDF